Vascular BioSciences
http://www.vascularbiosciences.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Vascular BioSciences
After Hemophilia Deal, UniQure Sees Zolgensma As Model For Huntington’s Gene Therapy
While M&A-hungry investors were disappointed in no sale, uniQure now aims to pivot toward Huntington’s – and sees Zolgensma as an example to follow.
BMS Scoops Cormorant In $520M Immuno-Oncology Deal
Bristol-Myers Squibb Co. has bolstered its immuno-oncology ambitions by acquiring IL-8 focused Cormorant Pharmaceuticals AB, the 4-year old Swedish biotech. Cormorant’s shareholders are getting $95M up front with the promise of a further $425M if milestones are achieved.
Recent Tech Transfer Deals (4/07)
Each month, Start-Up presents a survey of technology transfer deals--licensing agreements between companies and universities or other research institutions--in the fields of life sciences, including pharmaceuticals, medical devices, in vitro diagnostics and research/analytical instrumentation and reagents.
Disease Management: A Seamless Whole is the Goal
Despite its failures, disease management remains a compelling need, perhaps because it's so clear that payers and providers require something to organize the increasingly expensive fragmentation of the health care system.
Company Information
- Industry
- Medical Devices
- Other Names / Subsidiaries
-
- VBS, VBS Interventional, VBS Molecular Diagnostics, VBS Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice